Tandem Labs to Acquire PharmaKD
Under the agreement, Tandem Labs will retain key personnel, intellectual property portfolios, proprietary informatics, scientific instruments, and 7,000-square-feet of operational space from PharmaKD.
Tandem Labs will operate three facilities within the United States: Tandem Labs-Salt Lake City, Tandem Labs-New Jersey, and the new Tandem Labs-New England, formerly known as PharmaKD.
Tandem's expanded services will include metabolite profiling, identification, and quantitation; biomarker discovery and screening; protein-binding assays; and discovery bioanalytical support services.
DMDiscovery™ is a drug metabolism technology that is designed to increase the productivity of drug metabolite identification and quantitation.
MarkerScan™ is a biomarker discovery and screening process that identifies potential biomarkers that can be used to increase the understanding of disease, diagnosis, and predictive models as well as drug compound safety, efficacy, and side-effect profiles.
"As the costs increase yearly for developing and launching a new drug, we at Tandem Labs have vigorously investigated new technologies and services that will allow our clients to safely and cost-effectively bring new medicines to market," explains Dr. Denis Lin, president and CEO of Tandem Labs.
"PharmaKD has strong intellectual property portfolios that improve pharmaceutical research productivity, reduce costs, and increase the success rate of drug candidates."
"These portfolios coupled with Tandem's long-standing, client-centric, and innovative bioanalytical services will provide our clients with a more complete laboratory menu and a higher likelihood of success when investigating new chemical entities."
Adds Dr. Lily Li, president of PharmaKD and the newly appointed Laboratory Director of Tandem Labs-New England, "We are extremely pleased to merge with an innovative and growing company such as Tandem Labs."
"We believe Tandem Labs has the services, customer focus, and dedicated sales force needed for future expansion in the competitive pharmaceutical-support industry."